Oxidative modification of low-density lipoprotein (LDL) is one of the earliest events in
atherosclerosis. Oxidized LDL (oxLDL) represents a variety of modification of both lipid and …

Antiphospholipid antibodies are associated with arterial and venous thrombosis, recurrent
pregnancy loss, and thrombocytopenia. Although the antibodies have not been conclusively …

The antiphospholipid syndrome (APS) is characterized by the presence of pathogenic
autoantibodies against β2-glycoprotein-I (β2GPI). The factors causing production of anti …

Anticardiolipin antibodies (aCL) derived from the sera of individuals exhibiting the
antiphospholipid syndrome (APS) directly bind to beta 2-glycoprotein I (beta 2-GPI), which is …

Objective To clarify the association of autoantibodies against prothrombin with the clinical
manifestations of the antiphospholipid syndrome (APS) and with the presence of lupus …

Anticardiolipin antibodies (aCL) in the sera of patients with antiphospholipid syndrome
(APS) recognize an altered structure of β2-glycoprotein I (β2-GPI) interacting with solid …

Cardiolipins (CL) represent unique phospholipids of bacteria and eukaryotic mitochondria
with four acyl chains and two phosphate groups that have been implicated in numerous …

ANTIPHOSPHOLIPID ANTIBODIES ARE A HETEROGENEOUS GROUP of autoantibodies
that are detected by immunoassays and functional coagulation tests. The antigenic targets …

Oxidized low-density lipoprotein (oxLDL) is thought to promote atherosclerosis through
complex inflammatory and immunologic mechanisms that lead to lipid dysregulation and …

β 2-glycoprotein I (β 2-GPI) is a major antigen for antiphospholipid antibodies (Abs, aPL)
present in patients with antiphospholipid syndrome (APS). We recently reported (J. Lipid …